Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022) - Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C.Y.A.; Oh, D.Y.; Ponz-Sarvisé, M.; Yachnin, J.; Shell, S.A.; Cassier, P.; Dotan, E.; et al.